Aim: To construct and validate a mini-battery to discriminate between Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in patients seen at a hospital memory clinic. Methods: In a cohort of 310 subjects (137 with MCI and 173 with AD), the area under the receiver operating curve (AUC) was used to select the neuropsychologic diagnostic test battery subtests with the best overall performance, namely, the Mini-Mental State Examination (MMSE, 0.715), Logical Memory II (LMII, 0.721), Verbal Fluency Test (0.747), and Lawton index (0.742). A mini-battery test was constructed with the following formulation: FMLL = [(Fluency Test/17 + MMSE/30 + LMII/32 + Lawton/8)/4] × 100. Another cohort of 87 subjects with MCI and 100 with AD was used to validate the mini-battery and to calculate the psychometric properties. Results: The concurrent validity with Reisberg’s Global Deterioration Scale was r = 0.792 (p < 0.001). Cronbach’s alpha internal consistency was 0.6358. The AUC to diagnose MCI or AD was 0.879 (95% CI: 0.832–0.927; p < 0.001). Specificity for MCI diagnosis was 0.9 when FMLL scores were above 59% and 1 when scores were above 76%. Conclusion: The FMLL mini-examination is a useful tool to differentiate between MCI and AD in patients seen in a memory clinic.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.